Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 125 | 17 | 108 |
| Samples | 124 | 17 | 107 |
| Peptides | 92 | 14 | 80 |
Function
LINC02210-CRHR1 · LINC02210-CRHR1 readthrough
This locus represents naturally occurring readthrough transcription between neighboring genes CRHR1-IT1, CRHR1 intronic transcript 1 (Gene ID: 147081) and CRHR1, corticotropin releasing hormone receptor 1 (Gene ID: 1394) on chromosome 17. The readthrough transcript encodes a protein that shares sequence identity with the product of the CRHR1 gene. [provided by RefSeq, Dec 2016].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000634540 | P34998-5 | 125 | 92 |
Gene Properties
Recurrent Mutations
All 92 amino-acid changes on canonical ENST00000634540 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in LINC02210-CRHR1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in LINC02210-CRHR1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Melanoma | 0/210 0% | 16/1899 1% |
| Gastric Carcinoma | 1/74 1% | 12/1809 1% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 7/1390 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 4/810 0% |
| Endometrial Carcinoma | 0/42 0% | 3/612 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Colorectal Carcinoma | 2/143 1% | 12/3239 0% |
| Ovarian Carcinoma | 2/109 2% | 2/998 0% |
| Neuroblastoma | 1/87 1% | 4/1331 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Other Solid Cancers | 0/94 0% | 4/1515 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 4/1592 0% |
| Head and Neck Carcinoma | 0/85 0% | 4/1574 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Pancreatic Carcinoma | 0/89 0% | 3/1611 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 3/2550 0% |
| Neuroendocrine Tumour | 0/154 0% | 1/577 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 2/2534 0% |
| Other Blood Cancers | 0/61 0% | 3/2725 0% |
| Hepatocellular Carcinoma | 0/46 0% | 2/2210 0% |
| Breast Carcinoma | 1/144 1% | 2/3264 0% |
| Prostate Carcinoma | 0/13 0% | 2/2105 0% |
| B-Lymphoblastic Leukemia | 1/55 2% | 1/2640 0% |
| Kidney Carcinoma | 0/85 0% | 1/1862 0% |
Mutation Distribution
Where LINC02210-CRHR1 is mutated · all tissues, split by cell line vs tissue
How many mutations in LINC02210-CRHR1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
Mutations
All 125 mutations in LINC02210-CRHR1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|